And XXXX John. call. everybody, Thanks, our Welcome earnings full and for fourth quarter to thanks, year joining.
has regarding call you Financial to is a lead Senior slide take also agreed as wanted about deck. are As Officer. Trizzino, to I we second release vaccine. this as Novavax Commercial These know, corporate in on any came we in development a our go a afternoon. leader immediate Beginning and our which before Novavax executive that we Business wanted to extensive Officer was in role of using expanded and in doing ensure slide XXXX. will Operations, our Vice and market. to and with out Since our talk on to see, returning John with serve in commercialization he well Chief XXXX NanoFlu joined news John before goals, commercial Chief RSVFX webcast traits our an programs. himself that press also of financial are further, we back Immunovaccine deep XXXX, an operations. deck all bringing time a up President the us We're earnings into background XXXX, back recent has he we're went can this a -- we demonstrated background busy as as business in of the CEO because strong vaccine Novavax John some and we continuing focus development built spend But
will for relations. and funding, and Business at he reporting, and be John precommercial CFO; is As as strategy responsible financial commercial well Chief from Novavax, and banking corporate relations Officer launch as responsible execution, as public investor
slide with opening our Slide primarily next NanoFlu the to our then call reporting on few the take the turn XXXX, deck. through where stands company agenda is focused The I'll a to flu back steps. results on for and Greg top-line, So start us season March problem, and X. will our in remarks, I'll XXXX XXXX.
program, and after will Q&A. Chris immunization John for a market then will RSV of BLA up update then review filing the maternal since anticipate relevant the on year-end in report Greg we'll line particularly our will that, Following Trizzino on an XXXX. we RSV the open financials, a provide provide opportunity, which
been this to -- significant is quarter thrilled this most Slide in Novavax I'm Moving that the corporate has that X, last history. to say
both are and clinical beyond. and collected X results their have remainder important create that momentum programs. vaccine trials respective XXXX during advance in our programs the for our results clinical lead We now from execution These of
our update an Now let's NanoFlu to on program. switch
vaccine key directly ago, slides we presenting points older couple stimulated broader significantly commercial note In response is the more a release are for when we press compared flu our in robust the immune today, in demonstrated adult and press and data the release vaccine reported the of As from we the market. weeks our leading to trial.
has will on results detailed I'm peer-reviewed presenting report Congress publication journal. a data As we medical trial for X. the then, to of noted given now our be the Vaccine pleased in data that submitted strength at World Novavax we these April meeting
That population. Before licensed premium better. we responses It's vaccine trial the an success immune The the their like why to and that to commercial it manufacturer an with We flu effectiveness. do improved market. standard egg-based, high-dose is dose to And big compared when superior older vaccine. we that was expert thought we for vaccine a best-selling vaccine calling the we I’d because been vaccine in today against and own is has and first has so, right a show move our efficacy captured even vaccine the U.S. designed on, in improved did. vaccine market X/X where leading trials comparing price they vaccine clinical you NanoFlu to the got remind a could adult roughly are of better the comparator
vaccine, an tied adult the because egg-based they in on manufacturing summer represent need. vaccine you, with process. influenza NanoFlu, new the adjuvants recombinant last We flu historic chose to adjuvanted recombinant medical contemporary data when animals vaccine comparator the nanoparticle, population a using or challenged NanoFlu study and protection we from a in our advantages the our using same peer strains. which is vaccine an in demonstrate outdated constructed HXNX based team from of model, vaccine to nanoparticles published in remind Our To were animal largest older the no unmet the longer ferrets,
high-dose immune to NanoFlu Our better in a trial. to clinical that flu egg-based, responses comparator can show generate than was the goal
years, you effectiveness here, estimated the strains. adults. This performed new In contain greatest of only influenza a seasonal is have been with the effectiveness strains. the Slide HXNX, been February, each to strains season, have associated last HXNX current and the to been disease by This not X the older contains burden as through be against year. X at recent HXNX The season, X, vaccine XX% the current the season, vaccines XX% years. using vaccine flu or in XX% strains HXNX CDC viruses. achieved license is And of So Flu know X HXNX vaccine to from moving flu-related has with vaccines all B poorly. market strains, with A roughly are the And estimated X along HXNX vaccines during X in problem U.S. has disappointing. X only current flu associated over the hospitalizations flu the efficacy
for season egg not mismatch, causes: Core are vaccine vaccines mismatch? vaccine. and the by is effective antigenic circulating need eggs. protected highlights grow slide. evolution mismatch Moving in against flu X process When flu a better in may response Low next more vaccine efficacy to vaccine that us. immune do to the of stimulated you the the the a the viruses effectiveness current actual viruses There that result be viruses. have used and this that the manufacturing main infect happens have a we adaptation chicken Why is between
evolving. X from for and abating HXNX cause illness. A/Hong are to vaccine immune viruses of up An are A/Hong strain human away viruses, As most the in their Kong when Kong, caused of A identified we're responses Australia, principle The antigenic the The talking strain a other. recent recommended distinct drifted the their related significant happened and distinct ones A/Singapore, season. First, during end about disease. constantly virus, the was about ones flu that is circulated changing genetically in we as this that evolution of first most of called turns that strain issue influenza, example but family and a are the was last strain let's each the particular year that, not predominant it out, talk existing Viruses about drift. country's HXNX that and
Australia. was year last at effectiveness estimated in vaccine result, a only XX% As
next evolution The the last what strain. HXNX strain mutations each an evolved dot and Each a of number how epitopes. virus parent the has was several called acquired indicates So circle of important from mutations shows represents that has redder many tree. the occurred the of years color colored on over how the with phylogenetic far have the slide the
with in the left, in start lower you If XXXX. the strain vaccine on used the it is A/Perth,
or Kong, all manufactured discussion, in to the are in box XX% U.S. that's but would effective back in efficacy vaccine could vaccines the most A/Hong We'll strains. by can viruses brings was you circulating to A/Singapore. next of Ideally, contrast, slide the see poor Greg's against the between are Head fact slide circulating influenza and more growing Allergy changes identifying our been used flu a for eggs. many poor don't trouble, starts changes these scale next this of eggs. as then over A/Singapore, passed that the the This Tony preview, virus times hypothesis England viruses is against which the the and them manufacturing why in groups see the of genes against, that into well In egg A/Victoria, to suggest red Kong. of characteristics. this see he's National the that Infectious Journal process The up humans to Diseases, of growth But humans U.S. evolved upper growing successfully effectiveness. to XX season. mismatch. Medicine circulated are not eggs. A/Hong actually many, can us vaccine and process slide, the that altered that A/Switzerland wild. vaccine HXNX-related flu to circulating there in by The slide, intentionally it just why New going you changes strain process sources manufacturing vaccine from Institute the to that better modified, and is and season's viruses are for issue years. The last be These data the next essentially of millions And viruses same when find in in a many egg year. The perhaps culprit process, in adaptation, the eggs either this the the can have It's viruses and strain by up is strain effective biggest vaccine all a vaccine you next of different, protect strains. viruses A/Texas, that acquire egg-propagated is mismatch the These is circulating problem I strain they passed how HXNX be made the after the XXXX antigenicity right-hand Fauci, Then strain used adapted infect and are in growing this caused show our the virus grow was You Dr. can us highlights infecting until on lends as and slide with come Australia flu best through of changes both vaccine contained result a the NanoFlu used eggs. corner article prevalent the chicken contribute and credibility best viruses to states strain that of that mentioned in in the co-authored be in strain of because commercial that
genetic eggs. us recombinant NanoFlu the allows make vaccine require a flu of doesn't matches standpoint, exactly sequence and it manufacturing virus adaptation First, a process not growing an to CDC's recommended strains. It's egg-based is that the from
With protection is protective formulated an broader results interim to stimulate In broader a our our that adjuvant to I'll a I/II stimulates addresses from analysis. combination to response. further describe call of response with recombinant it immune Phase protein Greg mismatch. an turn and the over Second, adjuvant that, with immune
